New hope for breast cancer patients with weak hearts: heart-safe combo shows promise
NCT ID NCT06845319
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 34 times
Summary
This study tests a 12-18 week combination of chemotherapy (carboplatin and paclitaxel) and immunotherapy (pembrolizumab) for people with triple-negative breast cancer who cannot take standard anthracycline-based chemo because of heart conditions or high risk of heart damage. The goal is to see if this heart-safe approach can eliminate the tumor before surgery. About 43 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical University of South Carolina
RECRUITINGCharleston, South Carolina, 29425, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.